Weekly nab-paclitaxel in elderly patients with classic Kaposi sarcoma
| Autor: | Eleonora Iuliano, Maria Luci, Angelo Pomillo, Gian Luca Cervo, maria Aquila Santoro, Francesco Pontieri, Alessia Perricelli, Francesco Iuliano |
|---|---|
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 34:e22539-e22539 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e22539 |
| Popis: | e22539Background: Kaposi's sarcoma (KS) is a potentially life-threatening multifocal neoplasm that may represent a difficult therapeutic challenge in disseminated stages. Liposomal anthracyclines, or combination chemotherapy are widely used to treat this kind of patients.. The efficacy of taxanes (paclitaxel and docetaxel), as agents with antiangiogenic properties,has been described previously in the treatment of KS patients but the length of the infusion, the need for pre-medication with steroids and toxicity caused by solvents can limit their utilization , especially in elderly patients. Nab-paclitaxel has efficacy comparable with solvent-based taxanes without need for steroid premedication which can make it easier to tolerate .At the moment there are no studies on its efficacy and safety in older KS patients . Methods: After written informed consent was obtained a phase II trial was conducted with nab-paclitaxel in 6 patients with advanced-stage KS to assess its safety and antitumor activity. The mean ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|